Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy
Movement Disorders · 2023
DOI: 10.1002/mds.29339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, 2023. Verfasst von Shu-Yi Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Fronti…. Hauptthemen laut MEDLINE: Multiple System Atrophy, Parkinson Disease, Parkinsonian Disorders, Supranuclear Palsy, Progressive. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Development of disease‐modifying therapeutic trials of progressive supranuclear palsy (PSP) urges the need for sensitive fluid biomarkers.
Objectives
The objectives of this study were to explore the utility of plasma biomarkers in the diagnosis, differential diagnosis, and assessment of disease severity, brain atrophy, and tau deposition in PSP.
Methods
Plasma biomarkers were measured using a single‐molecule array in a cohort composed of patients with PSP, Parkinson's disease (PD), multiple system atrophy with predominant parkinsonism (MSA‐P), and healthy controls (HCs).
Results
Plasma neurofilament light chain (NfL) outperformed other plasma makers (ie, glial fibrillary acidic protein [GFAP], phosphorylated‐tau 181 [p‐tau181], amyloid‐β 1–40, amyloid‐β 1–42) in identifying PSP from HC (area under the curve [AUC] = 0.904) and from MSA‐P (AUC = 0.711). Plasma GFAP aided in distinguishing PSP from HC (AUC = 0.774) and from MSA‐P (AUC = 0.832). It correlated with brainstem atrophy and higher regional tau accumulation. However, plasma p‐tau181 neither helped in diagnosis nor was it associated with clinical or neuroimaging measures.
Conclusions
Plasma NfL and GFAP showed different values in differentiating PSP from HC or controls with other forms of neurodegenerative parkinsonism and detecting disease severity, brain atrophy, or tau deposition in PSP. © 2023 International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan Universi…
- Department of Neurology, The First Hospital of Jilin University, Changchun, China.
- Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China.
- PET Center, Huashan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Shu-Yi Huang, Wei Cheng, Chuan-Tao Zuo, Jin-Tai Yu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, S. Y., Chen, S. F., Cui, M., Zhao, M., Shen, X. N., Guo, Y., Zhang, Y. R., Zhang, W., Wang, H. F., Huang, Y. Y., Cheng, W., Zuo, C. T., Dong, Q., & Yu, J. T. (2023). Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy. Movement Disorders. https://doi.org/10.1002/mds.29339
Vancouver
Huang SY, Chen SF, Cui M, Zhao M, Shen XN, Guo Y, et al. Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy. Movement Disorders. 2023. doi:10.1002/mds.29339
BibTeX
@article{Huang2023,
author = {Huang, Shu-Yi and Chen, Shu-Fen and Cui, Mei and Zhao, Meng and Shen, Xue-Ning and Guo, Yu and Zhang, Ya-Ru and Zhang, Wei and Wang, Hui-Fu and Huang, Yu-Yuan and Cheng, Wei and Zuo, Chuan-Tao and Dong, Qiang and Yu, Jin-Tai},
title = {Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy},
journal = {Movement Disorders},
year = {2023},
doi = {10.1002/mds.29339}
}
EUVIMED